Allergology International最新文献

{"title":"Investigator-initiated, multi-center, single-arm, open-label study of the effectiveness of canakinumab in Japanese patients with Schnitzler syndrome.","authors":"Naotomo Kambe, Mayuko Yamamoto, Koji Takemura, Shin-Ichiro Kagami, Yoshie Kawahara, Hajime Yoshifuji, Tomoyasu Jo, Kazushi Izawa, Satoshi Nakamizo, Norimitsu Inoue, Tatsuya Ito, Yoko Amino, Yumiko Ibi, Satoshi Morita, Nobuo Kanazawa","doi":"10.1016/j.alit.2024.10.001","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.001","url":null,"abstract":"<p><strong>Background: </strong>Schnitzler syndrome is an adult-onset autoinflammatory disease characterized by an urticaria-like rash and monoclonal gammopathy with fever and fatigue. Although some treatments have shown efficacy in clinical trials, no approved treatment exists. We aimed to assess canakinumab, an anti-IL-1β monoclonal antibody, in Japanese patients.</p><p><strong>Methods: </strong>This phase II, multicenter, single-arm, open-label study enrolled five patients with active disease from four hospitals. Patients received a single subcutaneous dose of canakinumab 150 mg. The primary endpoint was the proportion of patients achieving a complete clinical response (CR), based on physician global assessment on Day 7. If a CR was not achieved on Day 7 or by 8 weeks post-treatment, the dose was increased to 300 mg. Dosing continued every 8 weeks until 24 weeks. The study also evaluated patient-reported disease activity and changes in acute inflammatory markers, including white blood cell count, neutrophil count, C-reactive protein concentration, and serum amyloid A level. Quality of life was assessed using the Dermatology Life Quality Index and the 36-item Short Form health survey. Safety was also evaluated.</p><p><strong>Results: </strong>Sixty percent (3/5) of patients had a CR on Day 7. One of the remaining two patients had a CR 7 days after the dose was increased to 300 mg. All five patients, including those who did not achieve a CR, showed improvement in inflammatory markers and quality of life scores, and no new adverse events were detected.</p><p><strong>Conclusions: </strong>In this trial, canakinumab showed a potential for usefulness in Japanese patients with Schnitzler syndrome.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical impact of asthma-COPD overlap in severe asthma.","authors":"Miho Wakazono, Hirokazu Kimura, Ichizo Tsujino, Nobuyasu Wakazono, Michiko Takimoto-Sato, Munehiro Matsumoto, Kaoruko Shimizu, Houman Goudarzi, Hironi Makita, Masaharu Nishimura, Satoshi Konno","doi":"10.1016/j.alit.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.alit.2024.11.003","url":null,"abstract":"<p><strong>Background: </strong>Patients with asthma-COPD overlap (ACO) have a greater symptom burden, worse respiratory function, and more frequent exacerbations than those with asthma alone. However, only a few studies have investigated the prevalence and clinical course of ACO in severe asthma. This study aimed to examine the comorbid rate of ACO and its clinical impact on severe asthma.</p><p><strong>Methods: </strong>We prospectively enrolled 127 patients with severe asthma from 30 hospitals and clinics. Favorable treatment adherence was ensured, and the prevalence of ACO was assessed using the Japanese Respiratory Society ACO criteria. Patients were categorized into two groups, ACO and non-ACO, and their clinical characteristics were compared. The exacerbation rates with a 3-year follow-up and the annual change in FEV₁ with a 5-year follow-up of 105 individuals were evaluated. The exacerbation-free rate was analyzed using the Kaplan-Meier method and the Cox proportional hazards model.</p><p><strong>Results: </strong>The prevalence of ACO in severe asthma was 31.5 %. Patients with ACO were older, more frequently male, and had a longer duration of asthma than those without. No significant difference was observed in exacerbation rates between the ACO and non-ACO groups (62.2 % vs. 63.2 %, P = 0.91) or the annual change in FEV₁ (-39.2 mL/year vs. -31.2 mL/year, P = 0.11).</p><p><strong>Conclusions: </strong>The prevalence of ACO in our multicenter cohort study on severe asthma was approximately 30 %. The presence of ACO was not an independent risk for exacerbations or decline in FEV₁.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial.","authors":"Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, Norihiro Harada, Yasunari Miyazaki, Hideki Katsura, Etsuko Tagaya, Junko Terada, Masayuki Hojo, Naoya Sugimoto, Hiroyuki Nagase, Yuta Kono, Hisato Hiranuma, Yasuhiro Gon, Ryo Takemura, Misato Irie, Reina Nakamura, Hiroki Kabata, Jun Miyata, Koichi Fukunaga","doi":"10.1016/j.alit.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.009","url":null,"abstract":"<p><strong>Background: </strong>Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe asthma.</p><p><strong>Methods: </strong>This prospective, interventional, single-arm clinical trial was conducted across ten facilities in Japan between September 2020 and July 2022. Adult patients with severe eosinophilic asthma (peripheral blood eosinophil count ≥150 cells/μl) were enrolled and treated with benralizumab. The primary endpoint was the change in ACQ-5 score from baseline to week 24.</p><p><strong>Results: </strong>Of 103 patients, 98 (mean age: 62.1 years, women: 55.1 %, regular oral corticosteroids [OCS] treatment: 20.4 %) were included in the analysis. From baseline to week 24, benralizumab significantly improved ACQ-5 (-0.67, 95 % CI: -0.94 to -0.39) and AQLQ (0.71, 95 % CI: 0.46 to 0.96) scores with an increase in FEV1 (87 ml, 95 % CI: 15-159 ml). The maintenance OCS dose and the percentage of OCS users decreased from 13.9 mg/day to 6.0 mg/day and from 20.4 % to 9.2 %, respectively. Multivariable analysis identified baseline blood eosinophil count (≥400 cells/μl) and fractional exhaled nitric oxide (≥22 ppb) as independent predictors of therapeutic response to benralizumab. Benralizumab treatment was discontinued due to nonserious adverse events and patient choice in four and three patients, respectively.</p><p><strong>Conclusions: </strong>In a real-world setting in Japan, patients with severe eosinophilic asthma treated with benralizumab demonstrated substantial improvements in asthma control, quality of life, and respiratory function with reduced OCS usage.</p><p><strong>Trial registration: </strong>Japan Registry of Clinical Trials (jRCTs031190237).</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and risk factors of non-esophageal eosinophilic gastrointestinal diseases in Japan: A population-based study.","authors":"Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Yasuhiro Fujiwara","doi":"10.1016/j.alit.2024.10.007","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.007","url":null,"abstract":"<p><strong>Background: </strong>Non-esophageal eosinophilic gastrointestinal diseases (non-EoE EGIDs) are allergic conditions where Th-2-predominant inflammation causes symptoms related to gastrointestinal tract dysfunction. No studies have reported the incidence of non-EoE EGIDs. In addition, little is known about the influence of lifestyle factors on the condition.</p><p><strong>Methods: </strong>We used a large health claim database from January 2005 to September 2022. Non-EoE EGIDs cases were identified on the basis of the International Classification of Diseases-tenth Revision code, K52.8. The incidence and prevalence of non-EoE EGIDs were estimated by Poisson and binomial distribution, respectively. For each case, 10 controls were randomly selected for a nested case-control study to identify potential risk factors of non-EoE EGIDs.</p><p><strong>Results: </strong>Of 15,200,895 individuals, 1,368 new cases of non-EoE EGIDs were identified. The incidence and prevalence of non-EoE EGIDs in 2022 were 3.07 (95% CI 2.67-3.52) per 100,000 person-years and 17.23 (95% CI 16.38-18.11) per 100,000 individuals, respectively, which were approximately 6 and 9 times higher than those in 2010. Allergic rhinitis (OR 1.63 (95% CI 1.16-2.29), p = 0.005), chronic sinusitis (OR 2.41 (95% CI 1.58-3.66), p < 0.001), and urticaria (OR 2.32 (95% CI 1.45-3.70), p < 0.001) were related to an increased risk of adult non-EoE EGIDs. Whilst atopic dermatitis (OR 2.28 (95% CI 1.35-3.86), p = 0.006) and the perinatal factors (OR 3.68 (95% CI 1.13-12.02), p = 0.031) were associated with an increased risk of pediatric non-EoE EGIDs. No association was seen with lifestyle factors such as obesity, smoking and alcohol consumption.</p><p><strong>Conclusions: </strong>The incidence and prevalence of non-EoE EGIDs have increased over the past two decades.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Japanese cedar pollen sensitization in children with Dermatophagoides pteronyssinus sensitization and maternal sensitization: Insights from the Yamanashi adjunct study within the Japan Environment and Children's Study (JECS).","authors":"Ayumi Shimamura, Ryoji Shinohara, Megumi Kushima, Sanae Otawa, Hideki Yui, Tomokazu Matsuoka, Daisuke Watanabe, Hiroshi Yokomichi, Kunio Miyake, Reiji Kojima, Zentaro Yamagata, Daiju Sakurai","doi":"10.1016/j.alit.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.alit.2024.11.002","url":null,"abstract":"<p><strong>Background: </strong>In recent years, the prevalence of allergic rhinitis (AR) in Japanese children has increased significantly. Multiple sensitization and genetic factors are associated with the development of AR, and moreover, multiply sensitized children are more likely to have parents with AR. This research investigated the association of Japanese cedar pollen (JCP) sensitization in children with Dermatophagoides pteronyssinus (DP) sensitization and with maternal JCP sensitization.</p><p><strong>Methods: </strong>This is an Adjunct Study to the Japan Environment and Children's Study (JECS) in Yamanashi where reports the highest positive rate of JCP sensitization. It included 1469 mother-child pairs who participated in a comprehensive health examination of 8-year-old children (from 2019 to 2022) at the JECS-Yamanashi. Univariate and multivariate logistic regression models were created using the presence/absence of child's JCP sensitization as the objective variable; mother's JCP sensitization and child's DP sensitization as explanatory variables; and child's sex and BMI, mother's age, and JCP exposure in the examination year as adjustment variables.</p><p><strong>Results: </strong>Children who were positive for DP sensitization were also more likely to be positive for JCP sensitization (adjusted OR: 6.58; 95%CI: 5.10-8.48; P < 0.001). Children who were positive for DP sensitization were also more likely to be positive for JCP sensitization if their mothers were positive for JCP sensitization (adjusted OR: 1.77; 95%CI: 1.16-2.71; P = 0.008).</p><p><strong>Conclusions: </strong>JCP sensitization is associated with DP sensitization in children. Furthermore, in DP sensitization-positive children, JCP sensitization of the child was associated with JCP sensitization of the mother.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Questionnaire survey among ophthalmic allergists on dupilumab-associated ocular surface disease in Japan.","authors":"Jun Shoji, Yousuke Asada, Rumi Adachi, Noriko Inada, Eiichi Uchio, Yoko Kataoka, Norito Katoh, Tatsuma Kishimoto, Eisuke Shimizu, Tamaki Sumi, Etsuko Takamura, Kenichi Namba, Yuuko Hara, Kazuhiro Harada, Akira Hirota, Atsuki Fukushima, Ken Fukuda, Hiroshi Fujishima, Moe Matsuzawa, Akira Matsuda, Tatsuya Mimura, Dai Miyazaki, Hiroyuki Yazu, Kaori Yamamoto, Kazuma Kitsu, Nobuyuki Ebihara","doi":"10.1016/j.alit.2024.10.004","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.004","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible role for obstructive sleep apnea in nocturnal episodes of idiopathic angioedema.","authors":"Evelien Maria Hutten, Annick Augustina Josephina Maria van de Ven, Rick Gert-Jan Pleijhuis","doi":"10.1016/j.alit.2024.11.001","DOIUrl":"https://doi.org/10.1016/j.alit.2024.11.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T follicular helper and memory B cells in IgE recall responses.","authors":"Joshua F E Koenig","doi":"10.1016/j.alit.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.003","url":null,"abstract":"<p><p>IgE antibodies raised against innocuous environmental antigens cause allergic diseases like allergic rhinitis, food allergy, and allergic asthma. While some allergies are often outgrown, others (peanut, shellfish, tree nut) are lifelong in the majority of individuals. Lifelong allergies are the result of persistent production of allergen-specific IgE. However, IgE antibodies and the plasma cells that secrete them tend to be short-lived. Persistent allergen-specific IgE titres are thought to be derived from the continued renewal of IgE plasma cells from memory B cells in response to allergen encounters. The initial generation of allergen-specific IgE is driven by B cell activation by IL-4 producing Tfh cells, but the cellular and molecular mechanisms of the long-term production of IgE are poorly characterized. This review investigates the mechanisms governing IgE production and Tfh activation in the primary and recall responses, towards the objective of identifying molecular targets for therapeutic intervention that durably inactivate the IgE recall response.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tristetraprolin-mediated mRNA destabilization regulates basophil inflammatory responses.","authors":"Junya Ito, Kensuke Miyake, Tomoki Chiba, Kazufusa Takahashi, Yutaro Uchida, Perry J Blackshear, Hiroshi Asahara, Hajime Karasuyama","doi":"10.1016/j.alit.2024.10.005","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.005","url":null,"abstract":"<p><strong>Background: </strong>Basophils, despite being the least common granulocytes, play crucial roles in type 2 immune responses, such as chronic allergic inflammation and protective immunity against parasites. However, the molecular mechanisms regulating basophil activation and inflammatory molecule production remain poorly understood. Therefore, we investigated the role of RNA-binding proteins, specifically tristetraprolin (TTP), in regulating inflammatory molecule production in basophils.</p><p><strong>Methods: </strong>Using antigen/IgE-stimulated basophils from wild-type (WT) and TTP-knockout (TTP-KO) mice, we performed bulk RNA sequencing, transcriptome-wide mRNA stability assays, and protein analyses. We also examined mRNA expression and protein production of inflammatory molecules in TTP-KO basophils under stimulation with IL-33 or LPS. Furthermore, we evaluated the in vivo significance of TTP in basophils using basophil-specific TTP-deficient mice and a hapten oxazolone-induced atopic dermatitis model.</p><p><strong>Results: </strong>TTP expression was upregulated in basophils following stimulation with antigen/IgE, IL-33, or LPS. Under these stimuli, TTP-KO basophils exhibited elevated mRNA expression of inflammatory molecules, such as Il4, Areg, Ccl3, and Cxcl2, compared to WT basophils. Transcriptome-wide mRNA stability assays revealed that TTP deficiency prolonged the mRNA half-life of these inflammatory mediators. Notably, the production of these inflammatory proteins was significantly increased in TTP-KO basophils. Moreover, basophil-specific TTP-deficient mice showed exacerbated oxazolone-induced atopic dermatitis-like skin allergic inflammation.</p><p><strong>Conclusions: </strong>TTP is a key regulator of basophil activation, controlling the production of inflammatory mediators through mRNA destabilization. Our in vivo findings demonstrate that the absence of TTP in basophils significantly aggravates allergic skin inflammation, highlighting its potential as a therapeutic target for allergic diseases.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic utility of Interleukin-22 in ocular surface testing for dupilumab-associated ocular surface disease.","authors":"Rumi Adachi, Jun Shoji, Akira Hirota, Akiko Tomioka, Koremasa Hayama, Noriko Inada, Satoru Yamagami","doi":"10.1016/j.alit.2024.10.002","DOIUrl":"https://doi.org/10.1016/j.alit.2024.10.002","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}